{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:30:07Z","timestamp":1790289007024,"version":"4.1.0"},"reference-count":20,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","award":["to institute\/ Not applicable"],"award-info":[{"award-number":["to institute\/ Not applicable"]}],"id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NHS England funding of National GTD service","award":["to institute \/ Not applicable"],"award-info":[{"award-number":["to institute \/ Not applicable"]}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["NIHR\/CRUK funding to Imperial Experimental Cancer"],"award-info":[{"award-number":["NIHR\/CRUK funding to Imperial Experimental Cancer"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2025,1,22]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To provide evidence for a reduced surveillance protocol to detect gestational trophoblastic neoplasia after normalisation of human chorionic gonadotrophin (hCG) levels following uterine evacuation of a complete hydatidiform mole.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>National retrospective population study<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Two UK Trophoblastic Disease Treatment Centres (Sheffield and London), 1 January 1980 to 30 November 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>17 424 patients with hCG normalisation after evacuation of their complete hydatidiform mole were included. Complete hydatidiform moles were verified by centralised pathological review. Patients were excluded if lost to follow-up or required treatment before normalisation of hCG levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>Incidence and clinical presentation of gestational trophoblastic neoplasia after normalisation of hCG levels following uterine evacuation of a complete hydatidiform mole.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 17 424 patients whose hCG normalised after complete hydatidiform mole evacuation, 99.8% (n=17\u2009393 of 17 424) did not subsequently develop gestational trophoblastic neoplasia. The overall risk of gestational trophoblastic neoplasia after previous normalisation of hCG levels was 0.2% (n=31 of 17 424 patients). The risk of developing gestational trophoblastic neoplasia after uterine evacuation was substantially lower if hCG levels returned to normal in &lt;56 days rather than \u226556 days (posterior medians 0.06%, 95% credible interval 0.01% to 0.14% <jats:italic>v<\/jats:italic> 0.22%, 0.15% to 0.31%), with a posterior relative risk of 0.25 (0.06 to 0.72). Most patients who developed gestational trophoblastic neoplasia (71.0%, n=22 of 31) had received a diagnosis after the current six month surveillance protocol. The cumulative risk of developing gestational trophoblastic neoplasia in patients whose hCG levels normalised early increased minimally with time. If a patient had normal hCG levels in &lt;56 days, a clinically relevant time point, the risk of developing gestational trophoblastic neoplasia was small (0.04%, about 1 in 2619 patients) at 39 months after normalisation. The equivalent risk for a patient who had normal hCG levels in \u226556 days was 0.16% (about 1 in 642 patients). All 31\u2009women who developed gestational trophoblastic neoplasia achieved sustained remission after subsequent treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The findings of the study indicate that surveillance protocols could safely change to one confirmatory normal hCG value for patients whose hCG levels return to normal in &lt;56 days of evacuation of a complete hydatidiform mole. Patients whose hCG levels return to normal in \u226556 days should be counselled on the remaining risk of gestational trophoblastic neoplasia over time to help decide the length of subsequent follow-up.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjmed-2024-001017","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T23:20:12Z","timestamp":1745450412000},"page":"e001017","source":"Crossref","is-referenced-by-count":8,"title":["Monitoring complete hydatidiform molar pregnancies after normalisation of human chorionic gonadotrophin: national retrospective population study"],"prefix":"10.1136","volume":"4","author":[{"given":"Brenna E","family":"Swift","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1680-3118","authenticated-orcid":false,"given":"Leonoor","family":"Coopmans","sequence":"additional","affiliation":[{"name":"Department of Gynaecologic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kam","family":"Singh","sequence":"additional","affiliation":[{"name":"Sheffield Trophoblastic Disease Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Coyle","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund H","family":"Wilkes","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, NHS North West London Pathology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Jabbar","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Maher","sequence":"additional","affiliation":[{"name":"Charing Cross Gestational Trophoblastic Centre, Imperial College London-Charing Cross Campus, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianne","family":"Aguiar","sequence":"additional","affiliation":[{"name":"Charing Cross Gestational Trophoblastic Centre, Department of Medical Oncology, Imperial College London-Charing Cross Campus, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Salman","sequence":"additional","affiliation":[{"name":"Division of Gynaecologic Oncology, London Health Sciences Centre, University of Western Ontario, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia E","family":"Palmer","sequence":"additional","affiliation":[{"name":"Sheffield Trophoblastic Disease Centre, Department of Gynecologic Oncology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sarwar","sequence":"additional","affiliation":[{"name":"Gestational Trophoblastic Centre, Department of Medical Oncology, Imperial College London-Charing Cross Campus, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reece","family":"Caldwell","sequence":"additional","affiliation":[{"name":"Gestational Trophoblastic Centre, Department of Medical Oncology, Imperial College London-Charing Cross Campus, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshan","family":"Ghorani","sequence":"additional","affiliation":[{"name":"Gestational Trophoblastic Centre, Department of Medical Oncology, Imperial College London-Charing Cross Campus, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baljeet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Pathology, Gestational Trophoblastic Centre, Imperial College London-Charing Cross Campus, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke E","family":"van Trommel","sequence":"additional","affiliation":[{"name":"Department of Gynaecologic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christianne A R","family":"Lok","sequence":"additional","affiliation":[{"name":"Department of Gynaecologic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Winter","sequence":"additional","affiliation":[{"name":"Sheffield Trophoblastic Disease Centre, Weston Park Cancer Centre, Department of Medical Oncology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4078-2599","authenticated-orcid":false,"given":"Michael J","family":"Seckl","sequence":"additional","affiliation":[{"name":"Charing Cross Gestational Trophoblastic Centre, Imperial College London-Hammersmith Hospitals Campus, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"2025080501070442000_4.1.e001017.1","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/0284186X.2018.1438653","article-title":"Temporal trends in incidence and outcome of hydatidiform mole: a retrospective cohort study","volume":"57","author":"Joneborg","year":"2018","journal-title":"Acta Oncol"},{"key":"2025080501070442000_4.1.e001017.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60280-2"},{"key":"2025080501070442000_4.1.e001017.3","doi-asserted-by":"crossref","first-page":"vi39","DOI":"10.1093\/annonc\/mdt345","article-title":"Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24 Suppl 6","author":"Seckl","year":"2013","journal-title":"Ann Oncol"},{"key":"2025080501070442000_4.1.e001017.4","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.12615"},{"key":"2025080501070442000_4.1.e001017.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.166"},{"key":"2025080501070442000_4.1.e001017.6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2017.12.008","article-title":"What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients","volume":"148","author":"Coyle","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2025080501070442000_4.1.e001017.7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0140-6736(86)90179-0","article-title":"Hydatidiform mole in England and Wales 1973-83","volume":"2","author":"Bagshawe","year":"1986","journal-title":"Lancet"},{"key":"2025080501070442000_4.1.e001017.8","first-page":"e1","article-title":"Management of Gestational Trophoblastic Disease: Green-top Guideline No. 38 - June 2020","volume":"128","year":"2021","journal-title":"BJOG"},{"key":"2025080501070442000_4.1.e001017.9","unstructured":"Berkowitz RS , Horowitz NS , Elias KM . Hydatidiform mole: Treatment and follow-up, 2024. Available: https:\/\/www.uptodate.com\/contents\/hydatidiform-mole-treatment-and-follow-up [Accessed 02 Feb 2024]."},{"key":"2025080501070442000_4.1.e001017.10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/1471-0528.16849","article-title":"The psychological impact of gestational trophoblastic disease: a prospective observational multicentre cohort study","volume":"129","author":"Blok","year":"2022","journal-title":"BJOG"},{"key":"2025080501070442000_4.1.e001017.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2007.01320.x"},{"key":"2025080501070442000_4.1.e001017.12","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2012-0047-OA"},{"key":"2025080501070442000_4.1.e001017.13","doi-asserted-by":"crossref","unstructured":"B\u00fcrkner P-C . brms: An R Package for Bayesian Multilevel Models Using Stan. J Stat Softw 2017;1\u201328. doi:10.18637\/jss.v080.i01","DOI":"10.18637\/jss.v080.i01"},{"key":"2025080501070442000_4.1.e001017.14","unstructured":"Kurz AS . Applied Longitudinal Data Analysis in Brms and the Tidyverse. 2023. Available: https:\/\/bookdown.org\/content\/4253"},{"key":"2025080501070442000_4.1.e001017.15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ygyno.2011.05.035","article-title":"Predicting gestational trophoblastic neoplasia (GTN): is urine hCG the answer?","volume":"122","author":"Alazzam","year":"2011","journal-title":"Gynecol Oncol"},{"key":"2025080501070442000_4.1.e001017.16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2013.03.010","article-title":"Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type","volume":"130","author":"Schmitt","year":"2013","journal-title":"Gynecol Oncol"},{"key":"2025080501070442000_4.1.e001017.17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2015.09.012","article-title":"Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation","volume":"139","author":"Braga","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2025080501070442000_4.1.e001017.18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/AOG.0000000000003566","article-title":"Gestational Trophoblastic Neoplasia After Human Chorionic Gonadotropin Normalization Following Molar Pregnancy: A Systematic Review and Meta-analysis","volume":"135","author":"Albright","year":"2020","journal-title":"Obstet Gynecol"},{"key":"2025080501070442000_4.1.e001017.19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ajog.2021.05.031","article-title":"Surveillance for gestational trophoblastic neoplasia following molar pregnancy: a cost-effectiveness analysis","volume":"225","author":"Albright","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"2025080501070442000_4.1.e001017.20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603416"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2024-001017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T08:07:16Z","timestamp":1754381236000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2024-001017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,4,23]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjmed-2024-001017"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2024-001017","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}